Inotek Consolidates, Bids CEO Adieu

Drug developer Inotek is closing several international offices and selling its Israeli manufacturing plant in an effort to focus its resources on four of its main clinical and preclinical programs, the Beverly, MA-based firm announced today. The company also announced a host of changes to its management, including the resignation of CEO Andrew Salzman, and the termination of a collaboration with Genentech.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy